Mesa Laboratories, Inc. (MLAB)

Mesa Laboratories' stock price experienced a significant decline in the past year. Mesa Laboratories affirmed its dividend of $0.16 on January 11, 2026. A second-quarter dividend of $0.16 was announced on January 10, 2026. Mesa Laboratories, Inc. declared a quarterly dividend, payable on March 16, 2026. Mesa Labs was scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. Wells Fargo maintained an "equal-weight" recommendation for MLAB. Wells Fargo raised Mesa Labs' price target to $83 from $75. Mesa Laboratories, Inc. announced it would release its third-quarter results on February 3, 2026. An upcoming dividend of $0.16 per share was noted. Last reported earnings were on September 29, 2025. Mesa Laboratories announced its first fiscal quarter results (1Q26) ended June 30, 2025, with revenues increasing 5.0% and non-GAAP core organic revenues growth of 3.7%. Mesa Laboratories announced it would issue a press release with financial results for the first fiscal quarter on July 2, 2025.

The provided search results do not contain explicit information detailing the demand seasonality for Mesa Laboratories, Inc.'s products and services. The nature of its business suggests a relatively stable demand driven by ongoing regulatory requirements and the continuous need for product quality and patient safety.

Mesa Laboratories, Inc. is a global leader in quality control and calibration products and services, serving the life sciences, healthcare, and industrial sectors. Founded in 1982, the company specializes in instruments and consumables for product quality, patient safety, and process optimization in regulated industries. The company operates through four business segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions.

Mesa Laboratories has a global presence with operations in North America, Europe, and the Asia Pacific. The company has manufacturing operations in North America and Europe. Its products are marketed by its sales personnel in the U.S., Canada, Europe, and Japan, as well as through distributors worldwide.

Mesa Laboratories has a strong reputation as a trusted provider of sterilization validation and monitoring solutions, particularly in regulated industries. The company is recognized as a global leader in providing essential quality control solutions. The company's revenue increased by 11.5% in FY25, reaching $240,978 thousand, with a 24.4% overall growth driven by the GKE acquisition, indicating continued market acceptance and trust in its offerings.

Mesa Laboratories, Inc. has a diverse ownership structure, with institutional investors holding a significant portion of the company's stock. As of December 23, 2025, there were 362 institutional owners and shareholders holding a total of 6,993,098 shares. Major institutional shareholders include Conestoga Capital Advisors, LLC, BlackRock, Inc., and Vanguard Group Inc. Approximately 81.51% of the company's stock is owned by Institutional Investors, 3.12% by Insiders, and 15.38% by Public Companies and Individual Investors. Insider sentiment for MLAB is positive, with 9 different insiders buying shares, and over the last year, insiders collectively bought or received $17.6M worth of shares.